Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Alonso Alconada, Lorena ^a   Muinelo Romay, Laura ^a   Madissoo, Kadri ^b,c   Diaz Lopez, Antonio ^d   Krakstad, Camilla ^b,c   Trovik, Jone ^b,c   Wik, Elisabeth ^b,c   Hapangama, Dharani ^e   Coenegrachts, Lieve ^f   Cano, Amparo ^d   Gil Moreno, Antonio ^g   Chiva, Luis ^h   Cueva, Juan ^a   Vieito, Maria ^a   Ortega, Eugenia ⁱ   Mariscal, Javier ^a   Colas, Eva ^g   Castellvi, Josep ^g   Cusido, Maite ^j   Dolcet, Xavier ⁱ   Nijman, Hans W ^k   Bosse, Tjalling ^l   Green, John A ^e   Romano, Andrea ^m   Reventos, Jaume ^g,n   Lopez Lopez, Rafael ^a   Salvesen, Helga B ^b,c   Amant, Frederic ^f   Matias Guiu, Xavier ⁱ   Moreno Bueno, Gema ^d,h   Abal, Miguel ^a   more..

^a Instituto de Investigación Sanitaria de Santiago de Compostela IDIS   (Spain)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h MD ANDERSON CANCER CENTER   (Spain)

ⁱ UNIVERSITY OF LLEIDA   (Spain)

^j INSTITUT UNIVERSITARI DEXEUS   (Spain)

^k UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^l LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^m MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

more..

Author keywords

Circulating tumor cells; Epithelial to mesenchymal transition; ETV5; High risk endometrial carcinomas; Stem cell

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; GROWTH DIFFERENTIATION FACTOR 15; HERMES ANTIGEN; HORMONE RECEPTOR; NOTCH1 RECEPTOR; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR ZEB1; DNA BINDING PROTEIN; ETV5 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

AGED; ALDH GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BRAF GENE; CANCER STAGING; CARCINOGENESIS; CD44 GENE; CELL ISOLATION; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CTNNB1 GENE; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIUM CANCER; EPITHELIAL MESENCHYMAL TRANSITION; ETV5 GENE; FEMALE; GDF15 GENE; GENE; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NOTCH1 GENE; PHENOTYPIC PLASTICITY; PIK3CA GENE; REAL TIME POLYMERASE CHAIN REACTION; RELA GENE; RUNX1 GENE; SNAI1 GENE; STEM CELL; STS GENE; TGFB1 GENE; UPREGULATION; ZEB1 GENE; ZEB2 GENE; ANIMAL; CELL SEPARATION; DISEASE MODEL; ENDOMETRIUM TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; PHENOTYPE; RISK FACTOR; TUMOR EMBOLISM;

ANIMALIA;

AGED; ANIMALS; CELL SEPARATION; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; ENDOMETRIAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PHENOTYPE; RISK FACTORS; TRANSCRIPTION FACTORS;

EID: 84934942475     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-223     Document Type: Article

References (36)

1. Yeramian A, Moreno-Bueno G, Dolcet X, Catasus L, Abal M, Colas E, Reventos J, Palacios J, Prat J, Matias-Guiu X: Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene 2013, 32:403-413. 10.1038/onc.2012.76
2. Paterlini-Brechot P: Organ-specific markers in circulating tumor cell screening: an early indicator of metastasis-capable malignancy. Future Oncol 2011, 7:849-871. 10.2217/fon.11.32
3. Alix-Panabieres C, Pantel K: Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013, 59:110-118. 10.1373/clinchem.2012.194258
4. Negin BP, Cohen SJ: Circulating tumor cells in colorectal cancer: past, present, and future challenges. Curr Treat Options Oncol 2010, 11:1-13.
5. Costa C, Abal M, Lopez-Lopez R, Muinelo-Romay L: Biosensors for the detection of circulating tumour cells. Sensors (Basel) 2014, 14:4856-4875. 10.3390/s140304856
6. Barbazan J, Alonso-Alconada L, Muinelo-Romay L, Vieito M, Abalo A, Alonso-Nocelo M, Candamio S, Gallardo E, Fernandez B, Abdulkader I, de Los Ángeles Casares M, Gómez-Tato A, López-López R, Abal M: Molecular characterization of circulating tumor cells in human metastatic colorectal cancer. PLoS One 2012, 7:e40476. 10.1371/journal.pone.0040476
7. Barbazan J, Vieito M, Abalo A, Alonso-Alconada L, Muinelo-Romay L, Alonso-Nocelo M, Leon L, Candamio S, Gallardo E, Anido U, Doll A, De los Ángeles Casares M, Gómez-Tato A, Abal M, López-López R: A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer. J Cell Mol Med 2012, 16:2342-2349. 10.1111/j.1582-4934.2012.01544.x
8. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:3213-3221. 10.1200/JCO.2007.15.8923
9. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791. 10.1056/NEJMoa040766
10. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008, 14:6302-6309. 10.1158/1078-0432.CCR-08-0872
11. Colas E, Muinelo-Romay L, Alonso-Alconada L, Llaurado M, Monge M, Barbazan J, Gonzalez M, Schoumacher M, Pedrola N, Ertekin T, Devis L, Ruiz A, Castellvi J, Doll A, Gil-Moreno A, Vazquez-Levin M, Lapyckyj L, Lopez-Lopez R, Robine S, Friederich E, Castro M, Reventos J, Vignjevic D, Abal M: ETV5 cooperates with LPP as a sensor of extracellular signals and promotes EMT in endometrial carcinomas. Oncogene 2012, 31:4778-4788. 10.1038/onc.2011.632
12. Monge M, Colas E, Doll A, Gonzalez M, Gil-Moreno A, Planaguma J, Quiles M, Arbos MA, Garcia A, Castellvi J, Llaurado M, Rigau M, Alazzouzi H, Xercavins J, Alameda F, Reventos J, Abal M: ERM/ETV5 up-regulation plays a role during myometrial infiltration through matrix metalloproteinase-2 activation in endometrial cancer. Cancer Res 2007, 67:6753-6759. 10.1158/0008-5472.CAN-06-4487
13. Salvesen HB, Haldorsen IS, Trovik J: Markers for individualised therapy in endometrial carcinoma. Lancet Oncol 2012, 13:e353-e361. 10.1016/S1470-2045(12)70213-9
14. Ma PC, Blaszkowsky L, Bharti A, Ladanyi A, Kraeft SK, Bruno A, Skarin AT, Chen LB, Salgia R: Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Res 2003, 23:49-62.
15. Obermayr E, Sanchez-Cabo F, Tea MK, Singer CF, Krainer M, Fischer MB, Sehouli J, Reinthaller A, Horvat R, Heinze G, Tong D, Zeillinger R: Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer 2010, 10:666. 10.1186/1471-2407-10-666
16. Taylor SE, Green JA: Towards individualisation of treatment in endometrial cancer. Br J Cancer 2012, 106:1581-1582. 10.1038/bjc.2012.140
17. Mariani A, Dowdy SC, Keeney GL, Long HJ, Lesnick TG, Podratz KC: High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy. Gynecol Oncol 2004, 95:120-126. 10.1016/j.ygyno.2004.06.042
18. Lepine J, Audet-Walsh E, Gregoire J, Tetu B, Plante M, Menard V, Ayotte P, Brisson J, Caron P, Villeneuve L, Bélanger A, Guillemette C: Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. J Clin Endocrinol Metab 2010, 95:2689-2698. 10.1210/jc.2010-2648
19. Bosse T, Ter Haar NT, Seeber LM, Diest PJ, Hes FJ, Vasen HF, Nout RA, Creutzberg CL, Morreau H, Smit VT: Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod Pathol 2013, 26:1525-1535. 10.1038/modpathol.2013.96
20. Salvesen HB, Werner HM, Krakstad C: PI3K pathway in gynecologic malignancies. Am Soc Clin Oncol Educ Book 2013, 218-221.
21. Slomovitz BM, Coleman RL: The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 2012, 18:5856-5864. 10.1158/1078-0432.CCR-12-0662
22. Kang Y, Massague J: Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004, 118:277-279. 10.1016/j.cell.2004.07.011
23. Thiery JP, Morgan M: BREAST cancer progression with a TWIST. Nat Med 2004, 10:777-778. 10.1038/nm0804-777
24. Larue L, Bellacosa A: Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 2005, 24:7443-7454. 10.1038/sj.onc.1209091
25. Wik E, Raeder MB, Krakstad C, Trovik J, Birkeland E, Hoivik EA, Mjos S, Werner HM, Mannelqvist M, Stefansson IM, Oyan AM, Kalland KH, Akslen LA, Salvesen HB: Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clin Cancer Res 2013, 19:1094-1105. 10.1158/1078-0432.CCR-12-3039
26. Wicha MS, Liu S, Dontu G: Cancer stem cells: an old idea-a paradigm shift. Cancer Res 2006, 66:1883-1890. discussion 1895-1886 10.1158/0008-5472.CAN-05-3153
27. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S: Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009, 11:R46. 10.1186/bcr2333
28. Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D, Georgoulias V: Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 2010, 288:99-106. 10.1016/j.canlet.2009.06.027
29. Peacock CD, Watkins DN: Cancer stem cells and the ontogeny of lung cancer. J Clin Oncol 2008, 26:2883-2889. 10.1200/JCO.2007.15.2702
30. Mirantes C, Espinosa I, Ferrer I, Dolcet X, Prat J, Matias-Guiu X: Epithelial-to-mesenchymal transition and stem cells in endometrial cancer. Hum Pathol 2013, 44:1973-1981. 10.1016/j.humpath.2013.04.009
31. Castilla MA, Moreno-Bueno G, Romero-Perez L, Van De Vijver K, Biscuola M, Lopez-Garcia MA, Prat J, Matias-Guiu X, Cano A, Oliva E, Palacios J: Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol 2011, 223:72-80. 10.1002/path.2802
32. Brabletz S, Brabletz T: The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer? EMBO Rep 2010, 11:670-677. 10.1038/embor.2010.117
33. Wang G, Guo X, Hong W, Liu Q, Wei T, Lu C, Gao L, Ye D, Zhou Y, Chen J, Wang J, Wu M, Liu H, Kang J: Critical regulation of miR-200/ZEB2 pathway in Oct4/Sox2-induced mesenchymal-to-epithelial transition and induced pluripotent stem cell generation. Proc Natl Acad Sci U S A 2013, 110:2858-2863. 10.1073/pnas.1212769110
34. Kang Y, Pantel K: Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 2013, 23:573-581. 10.1016/j.ccr.2013.04.017
35. Chambers AF, Groom AC, MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-572. 10.1038/nrc865
36. Sorolla A, Yeramian A, Valls J, Dolcet X, Bergada L, Llombart-Cussac A, Marti RM, Matias-Guiu X: Blockade of NFkappaB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells. Mol Oncol 2012, 6:530-541. 10.1016/j.molonc.2012.06.006